These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 34564882

  • 61. Primary breast lymphoma: a single-institute experience in Taiwan.
    Ou CW, Shih LY, Wang PN, Chang H, Kuo MC, Tang TC, Wu JH, Lin TL, Hung YS, Dunn P.
    Biomed J; 2014; 37(5):321-5. PubMed ID: 25179707
    [Abstract] [Full Text] [Related]

  • 62. Lymphomas with kidney involvement: the French multicenter retrospective LyKID study.
    Kohn M, Karras A, Zaidan M, Bénière C, de Fréminville JB, Laribi K, Perrin MC, Malphettes M, Le Calloch R, Anglaret B, Martiniuc J, Bailly S, Chevret S, Molina T, Thervet E, Thieblemont C.
    Leuk Lymphoma; 2020 Apr; 61(4):887-895. PubMed ID: 32037948
    [Abstract] [Full Text] [Related]

  • 63. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK.
    Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
    [Abstract] [Full Text] [Related]

  • 64. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [Abstract] [Full Text] [Related]

  • 65. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK, Wang YP, Peng F, Zheng Y, Zou YB, Gao JN, Liu XL.
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [Abstract] [Full Text] [Related]

  • 66. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, Dimopoulos MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP.
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [Abstract] [Full Text] [Related]

  • 67. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ, Zhu X, Yang HY, Sun WY, Wu MJ.
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan 08; 47(1):32-38. PubMed ID: 29325248
    [Abstract] [Full Text] [Related]

  • 68. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model.
    Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y.
    Leuk Lymphoma; 2011 Dec 08; 52(12):2270-5. PubMed ID: 21745170
    [Abstract] [Full Text] [Related]

  • 69. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.
    Fleury I, Amorim S, Mounier N, Coiffier B, Dupuis J, Tilly H, Mazari MA, Filliatre L, Brière J, Brice P, de Kerviler E, Thieblemont C.
    Leuk Lymphoma; 2015 Jul 08; 56(7):2025-31. PubMed ID: 25347431
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis.
    Zhao J, Zhang W, Zhou D.
    Hematology; 2022 Dec 08; 27(1):757-764. PubMed ID: 35754389
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P.
    Blood; 2022 Apr 21; 139(16):2499-2511. PubMed ID: 34995350
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.
    Cancer; 2012 Jun 01; 118(11):2944-51. PubMed ID: 22006274
    [Abstract] [Full Text] [Related]

  • 77. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P, Jiang SY, He XH, Qin Y, Gui L, Zhou SY, Yang JL, Yang S, Wen TY, Shi YK.
    Zhonghua Zhong Liu Za Zhi; 2020 Mar 23; 42(3):234-241. PubMed ID: 32252203
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
    Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, Kinoshita T, Nakamura S.
    Ann Oncol; 2011 Jul 23; 22(7):1601-1607. PubMed ID: 21199885
    [Abstract] [Full Text] [Related]

  • 80. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
    Cao XX, Li J, Zhang W, Duan MH, Shen T, Zhou DB.
    Ann Hematol; 2014 Jun 23; 93(6):1001-5. PubMed ID: 24408160
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.